Duration of active psychosis and functional outcomes in first-episode non-affective psychosis

Eur Psychiatry. 2018 Aug:52:29-37. doi: 10.1016/j.eurpsy.2018.03.003. Epub 2018 Mar 31.

Abstract

Background: The duration of untreated psychosis (DUP) has been associated with negative outcomes in psychosis; however, few studies have focused on the duration of active psychotic symptoms after commencing treatment (DAT). In this study, we aimed to evaluate the effect of DUP and DAT on functional long-term outcomes (3 years) in patients with early psychosis.

Methods: We evaluated the Scale for the Assessment of Positive Symptoms (SAPS) at frequent intervals for 3 years after presentation to determine the DAT for 307 individuals with first-episode psychosis together with DUP and clinical variables. The functional outcomes were assessed using the Disability Assessment Scale (DAS) at three years, and functional recovery was defined as minimal impairment and return to activity. Associated variables, DAT and DUP were included in logistic regression models to predict functional outcomes. Receiver operating characteristic curves and Youden's index were applied to assess the best cut-off values.

Results: DAT, (Wald: 13.974; ExpB: 1.097; p < 0.001), premorbid adjustment, initial BPRS score, gender, age of onset and schizophrenia diagnosis were significant predictors of social functioning, whereas only premorbid adjustment (Wald: 11.383; ExpB:1.009), DAT (Wald: 4.850; ExpB: 1.058; p = 0.028) and education were significant predictors of recovery. The optimal cut-off of DAT for predicting social functioning was 3.17 months for DAT (sensitivity: 0.68; specificity: 0.64; Youden's index: 0.314).

Conclusions: DAT is strongly related to functional outcomes independent of the DUP period or other variables. As a modifiable variable, the reduction of the DAT should be considered a main focus of intervention from the onset of the illness to improve long-term outcomes.

Trial registration: ClinicalTrials.gov NCT02305823.

Keywords: Early intervention; Neurotoxicity hypothesis; Positive symptoms; Prognosis; Prospective study; Schizophrenia.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living / psychology
  • Adult
  • Antipsychotic Agents / therapeutic use
  • Cohort Studies
  • Disability Evaluation
  • Female
  • Humans
  • Male
  • Prospective Studies
  • Psychiatric Status Rating Scales
  • Psychotic Disorders / diagnosis
  • Psychotic Disorders / diagnostic imaging
  • Psychotic Disorders / psychology*
  • Schizophrenia / diagnosis*
  • Schizophrenia / drug therapy
  • Schizophrenic Psychology*
  • Social Adjustment*
  • Time Factors
  • Treatment Outcome

Substances

  • Antipsychotic Agents

Associated data

  • ClinicalTrials.gov/NCT02305823